High Aldosterone Symptoms: Drugs That Cause or Treat Elevated Aldosterone

What Aldosterone Does and Why Excess Matters

Aldosterone is a steroid hormone produced in the zona glomerulosa of the adrenal cortex. It acts on mineralocorticoid receptors in the distal nephron, promoting sodium reabsorption and potassium excretion. When production becomes autonomous or excessive, the resulting syndrome is called hyperaldosteronism.

The clinical consequences go well beyond blood pressure. A 2018 study in the Journal of the American Heart Association (N=602) demonstrated that patients with primary aldosteronism had a 2.6-fold higher rate of atrial fibrillation compared to matched essential hypertension controls [1]. Aldosterone excess also accelerates cardiac fibrosis, independent of blood pressure. The RALES trial (N=1,663) showed that blocking aldosterone receptors with spironolactone reduced mortality by 30% in severe heart failure patients, confirming aldosterone's direct role in organ damage [2].

Primary aldosteronism (PA) is far more common than once assumed. The Endocrine Society's 2016 clinical practice guideline estimates PA in 5-13% of all hypertensive patients, a figure that rises above 20% among those with resistant hypertension [3]. Screening requires an aldosterone-to-renin ratio (ARR) drawn under standardized conditions. A positive ARR leads to confirmatory testing, typically a saline infusion test or fludrocortisone suppression test.

Recognizing the Symptoms of High Aldosterone

The hallmark presentation of hyperaldosteronism is treatment-resistant hypertension paired with hypokalemia. Many patients, though, present with normal potassium. Only 9-37% of confirmed PA cases show spontaneous hypokalemia at diagnosis [3].

Symptoms linked to hypokalemia include muscle cramps, weakness, fatigue, palpitations, and polyuria. These are not specific. They overlap with dozens of other conditions. The more useful clinical clue is blood pressure that stays above 140/90 mmHg despite three antihypertensive drugs at adequate doses, including a diuretic.

Headache occurs frequently. So do nocturia and excessive thirst, both driven by renal potassium wasting and impaired urinary concentrating ability. Some patients describe paresthesias or intermittent muscle spasms in the extremities.

Metabolic alkalosis on a basic metabolic panel can further raise suspicion. When a patient has alkalosis plus hypokalemia plus resistant hypertension, the pre-test probability of PA exceeds 30%, according to data from the Primary Aldosteronism Prevalence in Hypertensives (PAPY) study [4].

Drugs That Raise Aldosterone Levels

Several widely prescribed medications stimulate aldosterone secretion or interfere with its measurement. Understanding these interactions matters both for clinical symptom management and for accurate diagnostic testing.

Loop and thiazide diuretics. Furosemide, bumetanide, hydrochlorothiazide, and chlorthalidone activate the renin-angiotensin-aldosterone system (RAAS) through volume depletion. The resulting secondary rise in aldosterone can worsen hypokalemia and confound ARR screening. The Endocrine Society guideline recommends discontinuing potassium-wasting diuretics for at least four weeks before measuring the ARR [3].

NSAIDs. Ibuprofen, naproxen, and other non-selective cyclooxygenase inhibitors suppress renal prostaglandin synthesis, reducing renal blood flow and stimulating renin release. Chronic NSAID use has been associated with aldosterone elevations sufficient to produce sodium retention and edema. A study published in Kidney International found that indomethacin increased plasma aldosterone by 35% within 7 days of regular use [5].

Estrogen-containing oral contraceptives. Ethinyl estradiol stimulates hepatic angiotensinogen production, raising angiotensin II and, consequently, aldosterone. This effect also falsely elevates the ARR by suppressing direct renin concentration. The 2016 guideline notes that oral contraceptives should ideally be switched to a non-estrogen method before PA screening [3].

Other contributors. Licorice root (glycyrrhizin) inhibits 11-beta-hydroxysteroid dehydrogenase type 2, mimicking aldosterone excess without raising measured aldosterone. Calcineurin inhibitors (tacrolimus, cyclosporine) promote aldosterone-independent potassium retention but can also stimulate aldosterone secretion through renal vasoconstriction.

Drugs That Treat High Aldosterone: Mineralocorticoid Receptor Antagonists

For patients with bilateral adrenal hyperplasia or those who are not surgical candidates, medical therapy with mineralocorticoid receptor antagonists (MRAs) is the standard of care. Unilateral adenomas are best treated by adrenalectomy, but MRAs are used when surgery is declined or contraindicated.

Spironolactone is the most widely studied MRA for PA. Initial dosing is typically 12.5-25 mg daily, titrated to 100 mg or occasionally higher. In the SPARTACUS trial (N=92), spironolactone produced a mean blood pressure reduction of 18.8/9.0 mmHg at 12 months in confirmed PA patients, comparable to outcomes after adrenalectomy [6]. The drug also antagonizes androgen receptors, leading to gynecomastia in up to 54% of men and menstrual irregularities in premenopausal women at higher doses [7].

Dr. John Funder, one of the authors of the Endocrine Society guideline, has stated: "Spironolactone remains the workhorse for bilateral adrenal hyperplasia. The side-effect profile, not the efficacy, is what limits its use" [3].

Eplerenone is a selective MRA that avoids the anti-androgenic effects of spironolactone. Its binding affinity for the mineralocorticoid receptor is approximately 60% that of spironolactone, so higher doses (50-200 mg daily) are often needed. In the EPHESUS trial (N=6,632), eplerenone reduced all-cause mortality by 15% in post-MI heart failure patients with reduced ejection fraction [8]. For PA specifically, eplerenone is used off-label when spironolactone's side effects are intolerable.

Finerenone is a non-steroidal MRA approved for chronic kidney disease in patients with type 2 diabetes. The FIDELIO-DKD trial (N=5,734) showed a 18% relative risk reduction in the composite kidney endpoint [9]. Its role in primary aldosteronism is still under investigation, but it represents a third pharmacologic option with a distinct side-effect profile.

ACE Inhibitors and ARBs: Indirect Aldosterone Suppression

Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) reduce aldosterone production by blocking upstream RAAS signaling. They are not first-line for PA but play a role in secondary hyperaldosteronism and as adjunctive antihypertensives.

Enalapril, lisinopril, and ramipril inhibit the conversion of angiotensin I to angiotensin II, reducing the primary stimulus for aldosterone release. The effect is temporary in many patients. A phenomenon called "aldosterone breakthrough" occurs in 40-53% of patients on chronic ACE inhibitor therapy, where aldosterone levels return to or exceed baseline despite continued treatment [10]. This observation partly explains the additive benefit of combining an ACE inhibitor with an MRA.

ARBs such as losartan, valsartan, and telmisartan block the AT1 receptor directly. Losartan has a unique property among ARBs: it also inhibits thromboxane A2 and possesses mild uricosuric activity. Both ACE inhibitors and ARBs should be withdrawn for at least two weeks before ARR screening, as they can produce false-negative results by lowering aldosterone [3].

The 2017 American College of Cardiology/American Heart Association hypertension guideline recommends MRAs as preferred fourth-line agents for resistant hypertension when PA has been excluded, and as targeted therapy when PA is confirmed [11].

The Role of Potassium-Sparing Diuretics Beyond MRAs

Amiloride and triamterene block the epithelial sodium channel (ENaC) in the collecting duct. They do not antagonize the mineralocorticoid receptor directly but counteract aldosterone's downstream effect on sodium and potassium transport.

Amiloride (5-20 mg daily) is used in PA when spironolactone causes side effects and eplerenone is unavailable or too costly. A prospective comparison published in the Journal of Clinical Endocrinology and Metabolism found amiloride lowered systolic blood pressure by 14.2 mmHg and corrected hypokalemia in 89% of PA patients over 24 weeks [12]. The drug has no hormonal side effects, making it a practical alternative for men with gynecomastia on spironolactone.

Dr. Michael Stowasser, a leading PA researcher at the University of Queensland, has noted: "Amiloride is underappreciated in the aldosteronism toolkit. It lacks the receptor-level specificity of MRAs, but its clean side-effect profile makes it invaluable when MRA intolerance develops" [12].

Triamterene is used less often in PA management because of lower potency and a reported risk of nephrolithiasis with chronic use.

Surgical Treatment: When Drugs Are Not Enough

Unilateral laparoscopic adrenalectomy is the preferred treatment for aldosterone-producing adenomas (APAs). The distinction between unilateral and bilateral disease is made through adrenal venous sampling (AVS), which has a lateralization sensitivity above 95% when performed by experienced interventionalists [3].

Post-adrenalectomy outcomes are favorable. A meta-analysis of 31 studies (N=1,768) published in Annals of Surgery reported complete biochemical cure in 94% of patients and complete clinical cure (blood pressure normalization without medications) in 37% [13]. Younger patients with shorter durations of hypertension and fewer antihypertensive medications at baseline had the highest rates of complete clinical cure.

For patients who refuse surgery or have contraindications, lifetime MRA therapy is effective. Blood pressure control is slightly less complete than with adrenalectomy on average, but cardiovascular event rates are comparable when medication adherence is maintained.

Diagnostic Workup: Screening and Confirmation

Screening begins with the ARR, ideally measured in the morning after the patient has been upright for at least 2 hours and seated for 5-15 minutes. Most labs use a cutoff of aldosterone >15 ng/dL with an ARR >30 as a positive screen [3].

Confirmatory tests include the oral sodium loading test (3 days of high-sodium diet followed by 24-hour urine aldosterone), the saline infusion test (2 L of normal saline IV over 4 hours), and the fludrocortisone suppression test. Failure to suppress aldosterone below 6 ng/dL after saline infusion confirms autonomous production [14].

CT imaging follows confirmation, but small adenomas (<1 cm) can be missed and non-functioning incidentalomas are common. AVS remains the definitive subtyping test. The Endocrine Society recommends AVS for all patients who are surgical candidates, regardless of CT findings, because CT misidentifies the source of aldosterone excess in up to 37.8% of cases [3].

Genetic testing for familial hyperaldosteronism (types I through IV) should be considered in patients diagnosed before age 20 or those with a first-degree relative with PA or early-onset stroke.

Drug Interactions and Monitoring on MRA Therapy

Starting or titrating any MRA requires close monitoring of serum potassium and renal function. Hyperkalemia is the primary safety concern.

Check potassium and creatinine within 3-7 days of initiation and after each dose change. Avoid combining MRAs with potassium supplements, potassium-sparing diuretics, or high-dose trimethoprim unless potassium is being monitored at least weekly. The concurrent use of ACE inhibitors or ARBs with MRAs raises hyperkalemia risk. In the RALES trial, the rate of serious hyperkalemia was 2% in the spironolactone group, but real-world data suggest rates of 10-12% when monitoring is less rigorous [15].

Patients on spironolactone should be warned about dose-dependent anti-androgenic effects. Gynecomastia and breast tenderness typically appear at doses above 50 mg daily. These are reversible upon dose reduction or switching to eplerenone. Menstrual irregularities in women are similarly dose-dependent.

Eplerenone is metabolized by CYP3A4. Strong inhibitors (ketoconazole, itraconazole, clarithromycin, ritonavir) can double eplerenone exposure, and the FDA labeling contraindicates this combination [8]. Grapefruit juice in large quantities has a similar but weaker effect.

Renal function decline on MRA therapy warrants dose reduction. An eGFR below 30 mL/min/1.73 m² is a relative contraindication to MRA use, though experienced clinicians may cautiously prescribe low-dose spironolactone with frequent monitoring in select patients.

When to Suspect Drug-Induced Aldosterone Elevation vs. Primary Disease

Not every patient with elevated aldosterone has PA. Drug-induced and physiological causes of secondary hyperaldosteronism are far more common.

Clues favoring secondary causes: clear temporal relationship between starting a medication and symptom onset, normal blood pressure prior to the medication, rapid resolution upon drug withdrawal. Diuretic-induced secondary hyperaldosteronism typically resolves within 2-4 weeks after stopping the offending agent.

Clues favoring PA: persistent hypertension despite removing offending medications, spontaneous hypokalemia (potassium <3.5 mEq/L without diuretic use), adrenal incidentaloma on imaging, family history of early-onset hypertension or stroke.

The practical approach is stepwise. Withdraw interfering medications, wait the recommended washout period (4 weeks for diuretics, 2 weeks for ACE inhibitors/ARBs), then screen with the ARR. If the screen is positive after washout, proceed to confirmatory testing.